NCT06776965 Ultra Processed Foods Consumption and Impact in Rheumatic Diseases.
| NCT ID | NCT06776965 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospices Civils de Lyon |
| Condition | Rheumatoid Arthritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 240 participants |
| Start Date | 2025-03-31 |
| Primary Completion | 2026-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 240 participants in total. It began in 2025-03-31 with a primary completion date of 2026-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Ultra-processed foods (UPF) represent one of the mainstays of today's diet. They are defined by the NOVA classification system. It was demonstrated that UPF consumption was associated with activity of inflammatory bowel diseases with underlying mechanisms not fully identified yet. It is suspected that UPF constituents could modify the gut microbiota, increase intestinal barrier permeability and directly engage immune surveillance systems, effects that could individually or synergistically increase the risk of immunomediated diseases. As some pathophysiological mechanisms are shared among IBD and rheumatic diseases, we have wondered if UPF consumption could be associated with increased risk of rheumatic disease and/or with their activity. Our primary aim will be to study the pattern of UPF consumption in patients with rheumatic diseases. Our secondary objectives will be to study the activity of diseases according to UPF consumption.
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years * chronic rheumatic disease (Rheumatoid arthritis, spondyloarthritis, osteoarthritis) * ability to perform questionnaires Exclusion Criteria: * Judicial protection measure * Refusal to participate in the study * Suffering from 2 rheumatic disease simultaneously
Contact & Investigator
Maxime AUROUX, MD
PRINCIPAL INVESTIGATOR
Hôpital Edouard Herriot
Frequently Asked Questions
Who can join the NCT06776965 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rheumatoid Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06776965 currently recruiting?
Yes, NCT06776965 is actively recruiting participants. Contact the research team at Maxime.auroux@chu-lyon.fr for enrollment information.
Where is the NCT06776965 trial being conducted?
This trial is being conducted at Lyon, France.
Who is sponsoring the NCT06776965 clinical trial?
NCT06776965 is sponsored by Hospices Civils de Lyon. The principal investigator is Maxime AUROUX, MD at Hôpital Edouard Herriot. The trial plans to enroll 240 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.